89639-98-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-3-nitrobenzyl alcohol is used as an intermediate for the synthesis of various pharmaceuticals, playing a crucial role in the development of new drugs. Its unique structure allows for the creation of a wide range of biologically active molecules, contributing to advancements in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-3-nitrobenzyl alcohol is employed as an intermediate in the production of agrochemicals. Its involvement in the synthesis of compounds with pesticidal properties makes it a valuable component in the development of effective crop protection agents.
Used in Organic Synthesis:
2-Chloro-3-nitrobenzyl alcohol is used as a building block in organic synthesis for the preparation of a diverse array of organic compounds. Its versatility in forming different chemical structures makes it an essential component in the synthesis of complex organic molecules.
Used in Research of Organic Chemistry:
2-Chloro-3-nitrobenzyl alcohol is also utilized as a reagent in the synthesis of molecules with biological activity, making it instrumental in the research of organic chemistry. Its application in the development of new synthetic methods and the exploration of novel chemical reactions furthers the understanding and capabilities within the field of organic chemistry.

InChI:InChI=1/C7H6ClNO3/c8-7-5(4-10)2-1-3-6(7)9(11)12/h1-3,10H,4H2

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 3970-35-2 2-chloro-3-nitrobezoic acid 
• 53663-14-2 anhydro-2-hydroxymercuri-3-nitrobenzoic acid 

Downstream Products

• 112969-06-9 4-(2-chloro-3-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid dimethyl ester 
• 180080-64-2 N-(2-chloro-3-nitrophenylmethyl)iminodicarboxylic acid di-t-butyl ester 
• 89642-16-0 α-bromo-2-chloro-3-nitrotoluene 
• 1428248-64-9 C₄₈H₄₄N₆O₉ 
• 1428248-55-8 (S)-2-amino-N-(2-(tert-butyldimethylsilyloxy)ethyl)-N-(2-chloro-3-nitrobenzyl)-3-(1H-indol-3-yl)propanamide 
• 1428248-54-7 2-(tert-butyldimethylsilyloxy)-N-(2-chloro-3-nitrobenzyl)ethanamine 
• 1192040-18-8 tert-butyl (2E)-3-(2-chloro-3-nitrophenyl)prop-2-enoate 
• 1192040-19-9 tert-Butyl 3-(3-amino-2-chlorophenyl)propanoate 
• 108772-94-7 2,3-Bis-(2-chloro-3-nitro-phenyl)-propionitrile 
• 108772-95-8 2-chloro-3-nitrophenylacetonitrile 
• 866552-88-7 {2-(4-tert-butoxy-phenyl)-1-[[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-(2-chloro-3-nitro-benzyl)-carbamoyl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 866552-89-8 {2-(4-tert-butoxy-phenyl)-1-[(2-chloro-3-nitro-benzyl)-(1-hydroxymethyl-2-methyl-butyl)-carbamoyl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 857040-85-8 (2S)-2-amino-3-(4-tert-butoxyphenyl)-N-[2-(tert-butyldiphenylsilanyloxy)ethyl]-N-(2-chloro-3-nitrobenzyl)propionamide 
• 857040-87-0 (2S)-2-(4-tert-butoxybenzyl)-4-[2-(tert-butyldiphenylsilanyloxy)ethyl]-9-nitro-1,2,4,5-tetrahydrobenzo[1,4]diazepin-3-one 

Relevant academic research and scientific papers

General synthetic strategies towards N-alkyl sulfoximine building blocks for medicinal chemistry and the use of dimethylsulfoximine as a versatile precursor

The sulfoximine group has great potential as a substituent in drug discovery, as evidenced by two new clinical candidates, and can be viewed as an isosteric alternative to the commonly used sulfone. Our aim was to improve the accessibility of this group by synthesising a diverse range of S-alkyl and N-alkyl sulfoximine building blocks with procedures that are applicable on a practical scale (>10 g). In particular, synthesis of the less well exploited N-alkyl sulfoximines and the use of dimethylsulfoximine as a versatile, commercially available precursor is discussed.

Novel pseudopeptides incorporating a benzodiazepine-based turn mimetic - Targeting Mycobacterium tuberculosis ribonucleotide reductase

Peptides mimicking the C-terminus of the small subunit (R2) of Mycobacterium tuberculosis ribonucleotide reductase (RNR) can compete for binding to the large subunit (R1) and thus inhibit RNR activity. Moreover, it has been suggested that the binding of t

Carbazole inhibitors of histamine receptors for the treatment of disease

The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

New selective AT2 receptor ligands encompassing a γ-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists

New benzodiazepine-based γ-turn mimetics with one or two amino acid side chains were synthesized. The γ-turn mimetics were incorporated into angiotensin II (Ang II) replacing the Val3-Tyr4-Ile 5 or Tyr4-Ile

Aniline derivatives possessing an inhibitory effect of nitric oxide synthase

Compounds represented by the general formula (1): ? (where R1is SR6or NR7R8, where R6is typically an alkyl group having 1-6 carbon atoms, R7is a hydrogen atom, an alkyl group having 1-6 carbon atoms or a nitro group, and R8is a hydrogen atom or an alkyl group having 1-6 carbon atoms; R2and R3are each typically a hydrogen atom or an alkyl group having 1-6 carbon atoms; R4is a hydrogen atom, an alkyl group having 1-6 carbon atoms or an amidino group of which the amine portion may be substituted by an alkyl or nitro group; R5is a hydrogen atom or an alkyl group having 1-6 carbon atoms; Y1, Y2, Y3and Y4which may be the same or different are each typically a hydrogen atom, a halogen atom or an alkoxy group having 1-6 carbon atoms; n and m are each an integer of 0 or 1), or possible stereoisomers or optically active forms of the compounds or pharmaceutically acceptable salts thereof. The compounds possess a potent nitric oxide synthase inhibiting activity and are useful as therapeutics of cerebrovascular diseases.

Compounds useful in treating cytokine mediated diseases

Disclosed are amide compounds of formula(I): wherein Ar1, Q, Y and R3-R6 of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating d

Preparation and NMR analysis of 2,6-heterodifunctional halobenzenes as precursors for substituted biphenyls

Preparation and complete characterization of 16 2,6-disubstituted halobenzenes, including nine new compounds, from two common starting materials is described. Seven of the new compounds contain one or two propylthio groups, which have been introduced in two ways. Direct reaction of arenediazonium salts with 1-propanethiolate gives yields comparable to those obtained in a three-step method through sulfonyl chlorides. The 1H- and 13C NMR chemical shifts of 17 1,2,3-trisubstituted benzenes have been correlated with the predicted values and the observed trends explained using commonly available modeling packages.

Dihydropyrimidine macrocyclic lactones useful as calcium antagonists and agonists

A compound of the formula STR1 (symbols defined in the specification), its 3,4-dihydropyrimidine tautomer form and pharmaceutically acceptable salts thereof have calcium entry blocking activity. A process of preparation, pharmaceutical composition and met

NOVEL FENAMIC ACID METHYL HYDROXAMATE DERIVATIVES HAVING CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITION

The present invention is novel selected hydroxamic acid derivatives of fenamic acids having 5-lipoxygenase and cyclooxygenase inhibiting properties, pharmaceutical compositions for treating conditions advantageously affected by the inhibition and methods